Ivenix Inc. has closed on the first tranche of $50m in equity financing, which will put the company on track to pursue FDA approval for its Ivenix Infusion System.
The money should also help the company expand its team to begin commercialization, pending FDA approval of a technology that CEO Stuart Randle earlier described to Medtech Insight as a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?